The impacts of drug pricing strategies on patient access to medication / Senda Fattoum.

Format:

Book

Author/Creator:

Fattoum, Senda, author.

Series:

SAGE business cases.

SAGE business cases

Language:

English

Subjects (All):

Medical economics--United States--Case studies.

Medical economics.

Physical Description:

1 online resource.

Place of Publication:

London : SAGE Publications: SAGE Business Cases Originals, 2026.

Summary:

This case study explores the experience of Karen Winklers, a patient diagnosed with multiple sclerosis, who faces significant challenges in accessing necessary medications amidst rising prices influenced by strategic business practices in the pharmaceutical industry. It highlights two primary strategies used by large pharmaceutical manufacturers: "pay-for-delay" and "evergreening," particularly regarding the drug ProVigil produced by Cephalon. At its peak, Cephalon ranked among the leading biopharmaceutical companies in the world, with sales revenues of USD 2.8 billion in 2010. Notably, in October 2011, Teva Pharmaceuticals, one of the top-15 global pharmaceutical companies and a world leader in generic medicines, acquired Cephalon. This acquisition complicates the competitive landscape, as one company now controls both the brand name and generic versions of the drug. This case presents a multi-stakeholder examination including Winklers (the patient), Cephalon (the brand company), Teva Pharmaceuticals (the generic company), and policymakers (including the FDA). By analyzing these perspectives, the case aims to illustrate the ethical and legal complexities surrounding drug pricing strategies and their implications for patient access to medication.

Notes:

Description based on XML content.

ISBN:

979-83-488-1154-9

OCLC:

1569208746

Publisher Number:

T298810